Who Paid My Doc
Sripad Dhawlikar
Orthopaedic Surgery of the Spine Toms River, NJ Medical Doctor
NPI 1659327898 CMS profile 74402
530 Lakehurst Rd Ste 101, Toms River, NJ 08755
General payments
$6,111
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Sripad Dhawlikar of Toms River, NJ is reported in the CMS Open Payments database as having received $6,111 across 128 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 37th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $731 | 32 | |
| 2024 | General | $3,513 | 40 | |
| 2023 | General | $901 | 21 | |
| 2022 | General | $178 | 12 | |
| 2021 | General | $289 | 7 | |
| 2020 | General | $19 | 3 | |
| 2019 | General | $480 | 13 |
Beside peers
- Sripad Dhawlikar
- Orthopaedic Surgery of the Spine median
- Middle half of Orthopaedic Surgery of the Spine
- National median
In program year 2025, general payments to Sripad Dhawlikar were reported at $731. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.
Show as a table
| Year | Sripad Dhawlikar | Orthopaedic Surgery of the Spine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $480 | $2,106 | $337–$18,608 | $163 |
| 2020 | $19 | $1,213 | $156–$15,082 | $114 |
| 2021 | $289 | $1,834 | $271–$15,617 | $132 |
| 2022 | $178 | $2,015 | $320–$17,036 | $149 |
| 2023 | $901 | $1,925 | $336–$14,599 | $160 |
| 2024 | $3,513 | $2,110 | $341–$12,483 | $164 |
| 2025 | $731 | $2,061 | $347–$14,651 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
1,157
Drug cost
$5,669
Branded share of claims
15%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gabapentin | Generic | 93 | $974 | |
| Meloxicam | Generic | 276 | $921 | |
| Celecoxib | Generic | 31 | $852 | |
| Tramadol Hcl | Generic | 284 | $586 | |
| Oxycodone Hcl | Generic | 17 | $534 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 117 | $528 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 57 | $452 | |
| Cyclobenzaprine Hcl | Generic | 34 | $301 | |
| Cephalexin | Generic | 92 | $177 | |
| Methylprednisolone | Generic | 25 | $137 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 92 billing codesPaid by Medicare
$787,904
Medicare patients
852
Services billed
23,949
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 45% | |
| Ischemic heart disease | 43% | |
| COPD | 27% | |
| Depression | 27% | |
| Osteoporosis | 26% | |
| Chronic kidney disease | 25% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml Q9965 | Office | 367 | 5,218 | $5,940 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 391 | 5,997 | $4,692 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 136 | 7,640 | $770 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 132 | 1,362 | $404 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 39 | 42 | $197 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 64 | 805 | $72 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
128 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Orthopaedic Surgery of the Spine in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Surgery of the Spine
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.